Company news
Immuneering Corporation (NASDAQ:IMRX) news
Immuneering Corporation news releases on 6ix. Latest, Dec 19, 2024: Immuneering Launches Pancreatic Cancer Advisory Board
Press releases — page 2
Immuneering Launches Pancreatic Cancer Advisory Board
December 18, 2024
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma
December 11, 2024
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 12, 2024
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
October 14, 2024
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients
September 11, 2024
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 5, 2024
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
July 30, 2024
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
May 6, 2024
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
March 26, 2024
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors
March 13, 2024
Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors
March 11, 2024
Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors
March 10, 2024
Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
February 29, 2024
Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer
February 19, 2024
Immuneering Announces Participation in February Investor Conferences
January 31, 2024
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
December 11, 2023
Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates
November 8, 2023
Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference
October 11, 2023
Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 3, 2023
Immuneering Reports Second Quarter 2023 Financial Results and Provides Business Updates
August 2, 2023
Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid Tumors
June 4, 2023
Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates
May 3, 2023
Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline
April 17, 2023
Immuneering Announces $30 Million Underwritten Offering
April 17, 2023
Immuneering Appoints Harold E. Brakewood as Chief Business Officer
March 27, 2023
Immuneering Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
March 5, 2023
Immuneering to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates
February 26, 2023
Immuneering Announces First Patient Dosed in its Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations
November 27, 2022
Immuneering Reports Third Quarter 2022 Financial Results and Recent Business Highlights
November 9, 2022
Immuneering Announces Participation in November Investor Conferences
November 2, 2022
Immuneering Appoints Leah R. Neufeld as Chief People Officer
October 19, 2022
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations
September 29, 2022
Immuneering Announces Submission of IND Application to the FDA for Phase 1/2a Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations
September 1, 2022
Immuneering Reports Second Quarter 2022 Financial Results and Recent Business Highlights
August 9, 2022
Immuneering Reports Data in Two Preclinical Abstracts at the ASCO 2022 Annual Meeting Highlighting Pan-KRAS/NRAS Activity of IMM-1-104
May 25, 2022
Immuneering Announces Participation in Upcoming Investor Conferences
May 19, 2022
Immuneering Reports First Quarter 2022 Financial Results and Recent Business Highlights
May 9, 2022
Immuneering Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates
March 9, 2022
Immuneering Announces Participation in March Investor Conferences
February 23, 2022
Immuneering Strengthens Board of Directors with the Appointment of Diana F. Hausman, M.D.
January 17, 2022
Immuneering Reports Compelling Preclinical Data on IMM-1-104 in NRAS Mutant Melanoma Model And Will Host Key External Expert Investor Event
January 5, 2022
Immuneering Appoints Rimma Steinhertz, Ph.D., PMP as Vice President, Project and Alliance Management
January 2, 2022
Immuneering Reports Third Quarter 2021 Financial Results and Recent Business Highlights
November 8, 2021
Immuneering Reports Compelling Preclinical Data on IMM-1-104 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 10, 2021
Immuneering Announces Inclusion in the Russell 2000® Index
September 19, 2021
Immuneering Reports Second Quarter 2021 Financial Results and Provides Business Updates
September 8, 2021
Immuneering Announces Closing of its Upsized Initial Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
August 2, 2021